Terazosin Capsule
Product Images NDC 42291-823

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 42291-823). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1mg (820 10 1mg)

Terazosin Capsules USP 1 mg oral capsules by AvKARE. The label shows the product name, strength of 1 mg, and indicates a package size of 1000 capsules. The label includes the NDC number 42291-820-10 and directions to dispense with patient information. Storage and handling instructions are also partially visible.*

FDA Label Image

2mg (821 10 2mg)

Terazosin Capsules, USP 2 mg oral capsules label by AvKARE. The label includes dispensing instructions and storage conditions, states the capsule contains Terazosin Hydrochloride, and specifies a package size of 1000 capsules. The design features the AvKARE logo and NDC 42291-821-10.*

FDA Label Image

5mg (822 10 5mg)

Terazosin Capsules USP 5 mg oral capsules label by AvKARE. The label includes dosage strength 5 mg, package size of 1000 capsules, NDC 42291-822-10, and instructions for pharmacists to dispense with patient information sheet. It contains terazosin hydrochloride as the active ingredient.*

FDA Label Image

10mg (823 10 10mg)

Label for Terazosin Capsules, USP 10 mg by AvKARE. The product is an oral capsule with a quantity of 1000 capsules per package. Instructions to dispense with a patient information sheet and storage guidance are visible, along with a barcode and NDC number 42291-823-10.*

FDA Label Image

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure of Terazosin Hydrochloride, showing its molecular framework with aromatic rings, amine group, morpholine ring, and hydrochloride component.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

This figure shows two line graphs comparing Terazosin and placebo over a 3-month period. The left graph illustrates mean changes in total symptom score from baseline, with Terazosin showing a greater decrease than placebo. The right graph depicts mean increase in peak flow rate (mL/sec) from baseline, with Terazosin demonstrating a higher increase compared to placebo.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

A line graph depicting mean change from baseline over months, with data points marked from month 0 to month 30. The vertical axis shows values ranging from 0 to -7, and certain points are marked with asterisks indicating statistical significance. The chart appears to show a decrease that stabilizes over time.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

A line graph depicting mean change from baseline in an unspecified measure over 30 months. The x-axis represents time in months, and the y-axis shows mean change from baseline (units not specified). Data points include error bars, with several points marked by asterisks indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.